EBSCO Logo
Connecting you to content on EBSCOhost
Title

A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma.

Authors

Cytryn, Samuel Louis; Maron, Steven Brad; Janjigian, Yelena Y.

Publication

Journal of Clinical Oncology, 2025, Vol 43, pTPS515

ISSN

0732-183X

Publication type

Academic Journal

DOI

10.1200/JCO.2025.43.4_suppl.TPS515

EBSCO Connect | Privacy policy | Terms of use | Copyright | Manage my cookies
Journals | Subjects | Sitemap
© 2025 EBSCO Industries, Inc. All rights reserved